Application Deadline:
Explore other Industry Opportunities:
Strategic Area of Interest for Sponsored Research
Modality / Technology
- Diseases that can be applicable by Daiichi Sankyo’s original modality suitable for protease
- Drug delivery technologies for Daiichi Sankyo’s siRNA to the brain, heart, lung (macrophages), and kidney (tubular cells)
- Proximity inducing heterobifunctional compounds and molecular glues (other than conventional E3 ligase degrader)
- Novel technologies for identifying functional RNA-targeting small molecules
- Novel genome/RNA editing technologies
- Novel in vivo cell engineering technologies (e.g. CAR-T/M-based therapy)
Oncology Area
- Tumor-specific binders
- Unique methods for discovering tumor-specific binders (e.g. 3D conformation)
- Novel multi-specific binders (e.g. proximity)
- Tumor-specific functional modalities
- Tumor microenvironment-dependent functional molecules (e.g. binding/assembling control)
- Novel modalities with high penetration and retention in tumor stroma
Non-Oncology Area
(CNS, Liver, Fibrosis, HF)
- Novel research for identifying disease-relevant targets using patient tissue samples
- Novel in vitro and in vivo models that recapitulate human pathological mechanisms/conditions
Note: Prioritize research activity, which could be applicable to AAV or siRNA, although any modality is in focus.